InventisBio Co. Ltd. A
InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company's drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the t… Read more
Market Cap & Net Worth: InventisBio Co. Ltd. A (688382)
InventisBio Co. Ltd. A (SHG:688382) has a market capitalization of $1.49 Billion (CN¥10.94 Billion) as of March 19, 2026. Listed on the SHG stock exchange, this China-based company holds position #7223 globally and #1204 in its home market, demonstrating a -5.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying InventisBio Co. Ltd. A's stock price CN¥18.91 by its total outstanding shares 578348491 (578.35 Million).
InventisBio Co. Ltd. A Market Cap History: 2022 to 2026
InventisBio Co. Ltd. A's market capitalization history from 2022 to 2026. Data shows growth from $1.05 Billion to $1.49 Billion (6.02% CAGR).
InventisBio Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how InventisBio Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.21x
InventisBio Co. Ltd. A's market cap is 6.21 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $1.19 Billion | $185.53 Million | -$283.98 Million | 6.43x | N/A |
| 2024 | $1.05 Billion | $168.79 Million | -$240.20 Million | 6.21x | N/A |
Competitor Companies of 688382 by Market Capitalization
Companies near InventisBio Co. Ltd. A in the global market cap rankings as of March 19, 2026.
Key companies related to InventisBio Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
InventisBio Co. Ltd. A Historical Marketcap From 2022 to 2026
Between 2022 and today, InventisBio Co. Ltd. A's market cap moved from $1.05 Billion to $ 1.49 Billion, with a yearly change of 6.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.49 Billion | -30.58% |
| 2025 | CN¥2.15 Billion | +104.81% |
| 2024 | CN¥1.05 Billion | -12.15% |
| 2023 | CN¥1.19 Billion | +14.01% |
| 2022 | CN¥1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of InventisBio Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.49 Billion USD |
| MoneyControl | $1.49 Billion USD |
| MarketWatch | $1.49 Billion USD |
| marketcap.company | $1.49 Billion USD |
| Reuters | $1.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.